253 related articles for article (PubMed ID: 23666694)
1. Flow cytometric monitoring of residual disease in acute leukemia.
Wood BL
Methods Mol Biol; 2013; 999():123-36. PubMed ID: 23666694
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
Li X; Du W; Liu W; Li X; Li H; Huang SA
APMIS; 2010 May; 118(5):353-9. PubMed ID: 20477810
[TBL] [Abstract][Full Text] [Related]
3. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
4. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometric determination of leukemia-associated marker combinations for the study of minimal residual disease.
Babusíková O; Glasová M; Kusenda J; Koníková E; Mésárosová A
Neoplasma; 1994; 41(6):305-13. PubMed ID: 7870213
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric detection of residual disease in acute leukemia by assaying blasts co-expressing myeloid and lymphatic antigens.
Syrjälä M; Anttila VJ; Ruutu T; Jansson SE
Leukemia; 1994 Sep; 8(9):1564-70. PubMed ID: 7522295
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes.
Olaru D; Campos L; Flandrin P; Nadal N; Duval A; Chautard S; Guyotat D
Cytometry B Clin Cytom; 2008 Jan; 74(1):17-24. PubMed ID: 18061947
[TBL] [Abstract][Full Text] [Related]
8. First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX.
Ikoma MR; Sandes AF; Thiago LS; Cavalcanti Júnior GB; Lorand-Metze IG; Costa ES; Pimenta G; Santos-Silva MC; Bacal NS; Yamamoto M; Souto EX;
Cytometry B Clin Cytom; 2015; 88(3):194-203. PubMed ID: 24753208
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
11. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
Digiuseppe JA
Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotyping of leukemia.
Campana D; Behm FG
J Immunol Methods; 2000 Sep; 243(1-2):59-75. PubMed ID: 10986407
[TBL] [Abstract][Full Text] [Related]
13. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis.
Rothe G; Schmitz G
Leukemia; 1996 May; 10(5):877-95. PubMed ID: 8656686
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic analysis of acute lymphocytic leukemia.
Riley RS; Massey D; Jackson-Cook C; Idowu M; Romagnoli G
Hematol Oncol Clin North Am; 2002 Apr; 16(2):245-99, v. PubMed ID: 12094473
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
16. Combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in acute leukaemia.
Drach J; Gattringer C; Huber H
Br J Haematol; 1991 Jan; 77(1):37-42. PubMed ID: 1998595
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
Wood BL
Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
[TBL] [Abstract][Full Text] [Related]
18. [Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia].
Chen T; Zhu Y; Zhou X; Wang Y; Ying D
Zhonghua Xue Ye Xue Za Zhi; 2001 Jan; 22(1):20-3. PubMed ID: 11877045
[TBL] [Abstract][Full Text] [Related]
19. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
